The NSW Government has committed $96 million to establish an RNA Pilot Manufacturing Facility, which will translate research strengths into a sustainable commercial pipeline of RNA therapeutics and products. This unique Good Manufacturing Practice (GMP) Facility will manufacture potential RNA therapeutics (including, but not limited to, vaccines) for Phase 1 to 3 clinical trials using sRNA and mRNA processes. The Facility will have the potential to increase to population-scale production of vaccine or other medical therapeutics.
The NSW Government has opened a Registration of Interest for the Operator of the RNA Pilot Manufacturing Facility. For further information on the Registration of Interest, including participating in this process, please contact the Health Infrastructure RNA Project: HI-RNA@health.nsw.gov.au.
The Registrations of Interest are now closed.